Anti-proliferative effects of the combination of the investigational Aurora A kinase inhibitor alisertib and the MEK inhibitor TAK-733 were evaluated by SRB in cell lines representing 4 distinct molecular subtypes of CRC: KRAS/PIK3CA mutant (MT), KRAS MT/PIK3CA WT, KRAS WT/PIK3CA WT, and BRAF MT. The gene discussed is PIK3CA; the disease is colorectal carcinoma.